Enhancing Drug Bioavailability and Solubility
Approximately 40% of drugs on the market place and a high percentage of APIs in development are poorly soluble. Optimization of drug solubility and BA of therapeutics stands as one of the top challenges faced by the pharmaceutical and biotech industry today. A number of new chemical entities (NCEs) and new biological entities (NBEs) in clinical development are facing challenges in late phase of development (Phase II) due to a poor release profile and inability to achieve the desired Bioavailability. Additionally, many pharmaceutical and biotech companies are heavily investing in strategies to extend patents and stifle generic competition at the outset of product life cycles.
From a technology standpoint, there are a number of Bioavailability-enhancement approaches strategies which are demonstrating success. These include drug solid dispersions, liposomal formulations, selfemulsification, nanoparticle utilization, chemical complexation, and the use of nanocarriers, excipients, and targeting carriers amongst others. Ultimately, industry is in need of an integrated range of formulation and delivery strategies that can be cost effectively implemented as a complete toolkit in the drug development process for a wide range of drugs.
By way of followup, this week’s available deck is titled “Enhancing Drug Bioavailability and Solubility” from Stephen Byrn at Purdue University. Steve was a past speaker at our Global Drug Bioavailability Enhancement Summit. This presentation overviews pharmaceutical formulation development strategies, patent opportunities for solubility solutions, addresses amorphous, nanoparticle & cocrystal technology, solubilization approaches for parenteral routes of administration and solubilities of crystalline drugs in polymers. It also addresses challenges and solutions for toxicology .formulation development. To view this presentation and other novel delivery and bioavailability enhancement approaches, click below.
Our goal is to help you improve the performance of your drug products. Would you like to learn new strategies to improve patient compliance, bioavailability, stability and efficacy, all while reducing dosage, cost and decreasing time-to-market?
Join the drug development industry’s leading drug development specialists this January at the 2020 Global Drug Bioavailability Enhancement Summit in San Diego (March 3-4, 2021). Hear from 30+ senior drug bioavailability pioneers and network with 120+ senior drug development innovators and walk away with over 2 years of new drug formulation and bioavailability enhancement approaches strategies in just 2 days!
Planning to attend? Register early and save $800 or sending a group? Register 3 and the 4th is FREE. Sign-up and Gain Access to:
- 30+ industry-led speaker faculty over 2 full days sharing innovative drug development take-home strategies
- 12+ hours of networking sessions and breaks over two full days to learn from network with pharmaceutical and biotech senior formulation, development and delivery professionals
- 120+ senior participants spanning pharma, biotech and specialty delivery & technology companies
- Dynamic Tech Showcase Hall with multiple leading manufacturing, formulation development, delivery and modeling experts
Join over 1300 senior drug product development professionals in our free Novel Drug Discovery & Development Group. Members of this rapidly growing group will benefit by gaining access to an exclusive network of industry and academic professionals within the drug development arena. Members specialize in discovery, development, formulation, delivery and commercialization of innovative drug products.
Want to hear multiple weekly drug product development strategies and approaches from leading organizations and experts? Subscribe here and receive new podcast episodes, presentations, white papers, tips and resources directly from Curtis & Coulter weekly to your inbox